Lutetium Lu-177 vipivotide tetraxetan
- Generic Name
- Lutetium Lu-177 vipivotide tetraxetan
- Brand Names
- Pluvicto
- Drug Type
- Small Molecule
- Chemical Formula
- C49H68LuN9O16
- CAS Number
- 1703749-62-5
- Unique Ingredient Identifier
- G6UF363ECX
- Background
Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, lutetium Lu-177, linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended lutetium Lu-177 vipivotide tetraxetan be granted marketing authorization for the treatment of prostate cancer. In December 2022, lutetium Lu-177 vipivotide tetraxetan was approved by the EMA.
- Indication
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Global Cancer Peptide Drugs Market
Global peptide cancer drug market expected to exceed $18 billion, with over 30 approved drugs and 230 in clinical trials. Peptides offer targeted, less toxic cancer treatments, combining biologics' specificity with small molecules' cost-effectiveness. Major players include Novartis and Roche, with US leading R&D, supported by FDA's expedited approvals.
Ratio Nets Potential $750M Radioligand Cancer Deal with Novartis
Ratio Therapeutics collaborates with Novartis for $745M to develop a next-gen SSTR2-targeting radiotherapeutic for cancer, leveraging Ratio’s radioligand therapy expertise and technology platforms.
Killing cancer cells with alpha particles could be the next frontier in treatment
Canadian researchers are part of global efforts to test targeted alpha therapy, a new cancer treatment using radioactive alpha particles to kill cancer cells more effectively and with less damage to healthy tissue. Several therapies are in final stages of testing and could be approved by Health Canada within a few years. Potential applications include pancreatic, prostate, breast, and neuroendocrine cancers. Challenges include production of rare radioactive isotopes and high costs, with treatments expected to cost tens of thousands of dollars per dose.
PSMA PET Scan: Detecting Recurring Prostate Cancer
A PSMA PET scan detects prostate cancer by targeting PSMA proteins, useful for identifying metastasis early, determining treatment candidacy for Lu-177 PSMA, and confirming cancer spread. It uses radiotracers to highlight cancer areas, often combined with CT or MRI for detailed imaging. Approved radiotracers include Flotufolastat F 18, Gallium 68 PSMA-11, and Piflufolastat F 18.
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings
Eli Lilly missed Q3 estimates, lowered guidance; Merck beat estimates, initiated phase III study; Pfizer beat estimates, raised 2024 guidance; AbbVie beat estimates, acquired Aliada, collaborated with EvolveImmune; Novartis beat estimates, raised 2024 expectations, FDA approved Scemblix expansion.
Big Pharma earnings hang hope on the next generation of blockbusters
Big Pharma companies like Pfizer, Johnson & Johnson, Biogen, and Novartis are focusing on new products to drive future growth amid patent cliffs and market challenges. Pfizer's Prevnar 20 holds strong market share despite competition, while J&J's Tremfya gains traction as Stelara faces biosimilar competition. Biogen's Leqembi struggles with uptake due to infrastructure challenges, and Novartis relies on new oncology drugs to offset patent expirations and price negotiations.
Novartis continues strong momentum in Q3 with 10% sales
Novartis Q3 2024 results: net sales +10% (cc, +9% USD), core operating income +20% (cc, +17% USD), driven by strong performance from Entresto, Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio. Operating income +123% (cc, +106% USD), net income +121% (cc, +111% USD), core EPS +20% (cc, +18% USD) to USD 2.06. Free cash flow USD 6.0 billion (+18% USD). Full-year 2024 guidance raised: net sales expected to grow low double-digit, core operating income high teens.
A real-world pharmacovigilance study of FDA adverse event reporting system events for ...
First study to report AEs associated with 177Lu-PSMA-617 using FAERS database, identifying 6266 reports. Death (60.82%) most frequent severe outcome. Significant signals align with VISION trial, emphasizing hematological AEs. Renal toxicity not directly reflected. AEs prone to occur shortly after administration, with majority being grades 1–2. Study limitations include FAERS voluntary reporting and potential bias.
University of Missouri initiative to boost radioisotope production
MU expands NCA Lu-177 production for cancer therapies, solidifying MURR's role as the sole U.S. producer and a leader in radiopharmaceutical production.
rADCs Could Take Cancer Treatment 'Magic Bullet' to a New Level
Companies are developing radiolabeled antibody-drug conjugates (rADCs) to target cancer cells directly, reducing side effects and treatment times. rADCs, which use antibodies to deliver radiation to cancer cells, are seen as an emerging modality in oncology. Despite challenges like supply and delivery hurdles, clinical trials are progressing, with promising interim results and FDA orphan drug designations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath